[1] Wei Z, He JW, Fu WZ, et al.Osteomalacia induced by long-term low-dose adefovir dipivoxil: Clinical characteristics and genetic predictors.Bone,2016 ,93:97-103.
[2] Frame B, Parfitt AM. Osteomalacia: current concepts. Ann Intern Med,1978,89:966-82.
[3] 郎江莉,朱思忆,余希杰.阿德福韦酯致低磷性骨软化症1例及文献回顾.中华骨质疏松和骨矿盐疾病杂志,2018,11:186-192.
[4] 李华珊,马红.肾功能损伤标志物及其在核苷(酸)类似物治疗中肾功能监测的应用.中华肝脏病杂志,2016,24:234-236.
[5] Kim du H,Sung DH,Min YK.Hypophosphatemic osteomalacia induced by low-dose adefovir therapy:focus on manifestations in the skeletal system and literature review.J Bone Miner Metab,2013,3l:240-246.
[6] Shimizu Y,Hiraoka A,Yamago H,et a1.Hypophosphatemia in patients with hepatitis B virus infection undergoing long-term adefovir dipivoxil herapy.Hepatol Res,2014,44:1081-1087.
[7] Terasaka T,Ueta E,Ebara H,et a1.Long-term observation of osteomalacia caused by adefovir-induced Fanconi S syndrome.Acta Med Okayama,2014,68:53-56.
[8] Lv Y, Li X, Liang S, et al. The clinical and pathological features of adefovir dipivoxil-related renal impairment. Clin Nephrol,2019,91:180-186. |
